Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Labcorp Holdings Inc. (LH)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Labcorp Holdings Inc..
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 920148.
Total stock buying since 2015: $1,043,003.
Total stock sales since 2015: $222,322,901.
Total stock option exercises since 2015: $77,979,648.
Table 3. Detailed insider trading at Labcorp Holdings Inc. (LH) , Part 3
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2021-02-04 | Schechter Adam H (President & CEO) | Option Ex | 3,506 | .00 | 0 |
| 2021-02-04 | Williams R Sanders (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Neupert Peter M (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Anderson Kerrii B (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 970 | .00 | 0 |
| 2021-02-04 | Belingard Jean-luc (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 373 | .00 | 0 |
| 2021-01-26 | Williams R Sanders (Director) | Option Ex | 1,300 | 98.49 | 128,037 |
| 2020-12-01 | Davis Jeffrey A. (Director) | Option Ex | 173 | .00 | 0 |
| 2020-11-06 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 588 | 214.59 | 126,178 |
| 2020-11-05 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 2,010 | .00 | 0 |
| 2020-11-05 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 2,010 | .00 | 0 |
| 2020-11-04 | Kirchgraber Paul R (CEO, Covance Drug Development) | Sale | 1,500 | 214.14 | 321,204 |
| 2020-11-02 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 2,006 | .00 | 0 |
| 2020-11-02 | Schechter Adam H (President & CEO) | Option Ex | 2,006 | .00 | 0 |
| 2020-11-02 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 9,024 | .00 | 0 |
| 2020-09-25 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 970 | .00 | 0 |
| 2020-07-08 | Williams R Sanders (Director) | Sale | 1,300 | 173.12 | 225,056 |
| 2020-07-08 | Williams R Sanders (Director) | Option Ex | 1,300 | 98.49 | 128,037 |
| 2020-07-02 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 435 | 170.00 | 73,950 |
| 2020-06-24 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 872 | 160.33 | 139,807 |
| 2020-05-05 | King David P (Director) | Sale | 31,250 | 160.00 | 5,000,000 |
| 2020-04-03 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 1,010 | .00 | 0 |
| 2020-03-10 | Seltz Judith C (EVP, CHRO) | Buy | 330 | 168.56 | 55,624 |
| 2020-02-28 | Seltz Judith C (EVP, CHRO) | Buy | 250 | 174.94 | 43,735 |
| 2020-02-21 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Sale | 297 | 189.65 | 56,325 |
| 2020-02-19 | Belingard Jean-luc (Director) | Sale | 26,479 | 189.76 | 5,024,760 |
| 2020-02-19 | Belingard Jean-luc (Director) | Option Ex | 3,100 | 77.19 | 239,289 |
| 2020-02-13 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 188 | 188.49 | 35,436 |
| 2020-02-13 | Williams R Sanders (Director) | Sale | 1,227 | 188.49 | 231,277 |
| 2020-02-12 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 516 | .00 | 0 |
| 2020-02-12 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 579 | .00 | 0 |
| 2020-02-12 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 2,869 | .00 | 0 |
| 2020-02-12 | Gilliland Dwight Gary (Director) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | Parham Richelle P (Director) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | Kong Garheng (Director) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 866 | .00 | 0 |
| 2020-02-12 | Schechter Adam H (President & CEO) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | Williams R Sanders (Director) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | King David P (Director) | Option Ex | 7,749 | .00 | 0 |
| 2020-02-12 | Neupert Peter M (Director) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | Anderson Kerrii B (Director) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 1,720 | .00 | 0 |
| 2020-02-12 | Belingard Jean-luc (Director) | Option Ex | 1,227 | .00 | 0 |
| 2020-02-12 | Berberian Lance (SVP, Chief Information Officer) | Option Ex | 2,939 | .00 | 0 |
| 2020-02-10 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 108 | 181.99 | 19,654 |
| 2020-02-10 | Van Der Vaart Sandra D (SVP, Global General Counsel) | Sale | 133 | 181.99 | 24,204 |
| 2020-02-07 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 297 | .00 | 0 |
| 2020-02-07 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 337 | .00 | 0 |
| 2020-02-07 | Van Der Vaart Sandra D (SVP, Global General Counsel) | Option Ex | 367 | .00 | 0 |
| 2020-02-07 | King David P (Director) | Option Ex | 4,220 | .00 | 0 |
| 2020-02-07 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 994 | .00 | 0 |
| 2020-02-07 | Berberian Lance (SVP, Chief Information Officer) | Option Ex | 297 | .00 | 0 |
| 2019-12-04 | Belingard Jean-luc (Director) | Option Ex | 3,271 | .00 | 0 |
| 2019-10-28 | King David P (President & CEO) | Sale | 30,177 | 165.23 | 4,986,115 |
| 2019-09-23 | Anderson Kerrii B (Director) | Sale | 2,600 | 171.85 | 446,810 |
| 2019-09-23 | Anderson Kerrii B (Director) | Option Ex | 2,600 | 98.49 | 256,074 |
| 2019-09-04 | Uthgenannt Lisa J (Chief Human Resources Officer) | Sale | 2,466 | 168.59 | 415,742 |
| 2019-09-04 | Uthgenannt Lisa J (Chief Human Resources Officer) | Option Ex | 2,466 | 130.60 | 322,059 |
| 2019-08-30 | Berberian Lance (SVP, Chief Information Officer) | Sale | 5,902 | 169.80 | 1,002,171 |
| 2019-08-05 | Williams R Sanders (Director) | Sale | 500 | 162.91 | 81,455 |
| 2019-07-08 | Van Der Vaart Sandra D (SVP, Global General Counsel) | Sale | 2,328 | 176.75 | 411,474 |
| 2019-07-08 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Sale | 5,563 | 176.75 | 983,260 |
| 2019-06-20 | Anderson Kerrii B (Director) | Sale | 3,100 | 170.00 | 527,000 |
| 2019-06-20 | Anderson Kerrii B (Director) | Option Ex | 3,100 | 77.19 | 239,289 |
| 2019-06-07 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Sale | 10,000 | 167.63 | 1,676,279 |
| 2019-05-09 | Mittelstaedt Robert E Jr (Director) | Option Ex | 306 | .00 | 0 |
| 2019-05-06 | Williams R Sanders (Director) | Sale | 500 | 162.20 | 81,100 |
| 2019-05-03 | Mittelstaedt Robert E Jr (Director) | Sale | 3,700 | 166.30 | 615,310 |
| 2019-05-03 | Mittelstaedt Robert E Jr (Director) | Option Ex | 3,700 | 64.42 | 238,354 |
| 2019-05-02 | Uthgenannt Lisa J (Chief Human Resources Officer) | Sale | 4,000 | 164.00 | 656,000 |
| 2019-04-03 | Ratliff John D (CEO, Covance Drug Development) | Option Ex | 2,424 | .00 | 0 |
| 2019-02-13 | Williams R Sanders (Director) | Sale | 1,038 | 147.00 | 152,586 |
| 2019-02-12 | Caveney Brian J (SVP, Chief Medical Officer) | Option Ex | 233 | .00 | 0 |
| 2019-02-12 | Uthgenannt Lisa J (Chief Human Resources Officer) | Option Ex | 256 | .00 | 0 |
| 2019-02-12 | Dodson Edward T (Principal Accounting Officer) | Option Ex | 196 | .00 | 0 |
| 2019-02-12 | Gilliland Dwight Gary (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | Parham Richelle P (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | Kong Garheng (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | Schechter Adam H (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | Williams R Sanders (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | King David P (President & CEO) | Option Ex | 3,513 | .00 | 0 |
| 2019-02-12 | Neupert Peter M (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | Anderson Kerrii B (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | Mittelstaedt Robert E Jr (Director) | Option Ex | 1,038 | .00 | 0 |
| 2019-02-12 | Belingard Jean-luc (Director) | Sale | 3,700 | 146.06 | 540,407 |
| 2019-02-12 | Belingard Jean-luc (Director) | Option Ex | 4,738 | 32.21 | 152,610 |
| 2019-02-11 | Uthgenannt Lisa J (Chief Human Resources Officer) | Option Ex | 604 | .00 | 0 |
| 2019-02-11 | Dodson Edward T (Principal Accounting Officer) | Option Ex | 450 | .00 | 0 |
| 2019-02-11 | Ratliff John D (CEO, Covance Drug Development) | Option Ex | 6,100 | .00 | 0 |
| 2019-02-11 | King David P (President & CEO) | Option Ex | 7,544 | .00 | 0 |
| 2019-02-11 | Eberts F Samuel Iii (Chief Legal Officer, Secretary) | Option Ex | 520 | .00 | 0 |
| 2019-02-11 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 4,877 | .00 | 0 |
| 2019-02-11 | Berberian Lance (SVP, Chief Information Officer) | Option Ex | 3,497 | .00 | 0 |
| 2019-02-07 | Uthgenannt Lisa J (Chief Human Resources Officer) | Option Ex | 327 | .00 | 0 |
| 2019-02-07 | Dodson Edward T (Principal Accounting Officer) | Option Ex | 247 | .00 | 0 |
| 2019-02-07 | Ratliff John D (CEO, Covance Drug Development) | Option Ex | 1,863 | .00 | 0 |
| 2019-02-07 | King David P (President & CEO) | Option Ex | 4,220 | .00 | 0 |
| 2019-02-07 | Eberts F Samuel Iii (Chief Legal Officer, Secretary) | Option Ex | 297 | .00 | 0 |
| 2019-02-07 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 993 | .00 | 0 |
| 2019-02-07 | Berberian Lance (SVP, Chief Information Officer) | Option Ex | 297 | .00 | 0 |
| 2018-11-27 | Williams R Sanders (Director) | Sale | 350 | 162.14 | 56,748 |
| 2018-11-05 | Anderson Kerrii B (Director) | Sale | 3,700 | 163.29 | 604,161 |
| 2018-11-05 | Anderson Kerrii B (Director) | Option Ex | 3,700 | 64.42 | 238,354 |
| 2018-09-04 | Gary M. Huff (CEO, LabCorp Diagnostics) | Option Ex | 153 | .00 | 0 |
| 2018-06-06 | Dodson Edward T (Principal Accounting Officer) | Sale | 13,000 | 183.35 | 2,383,563 |
| 2018-06-06 | Dodson Edward T (Principal Accounting Officer) | Option Ex | 13,000 | 84.86 | 1,103,180 |
| 2018-06-04 | Uthgenannt Lisa J (Chief Human Resources Officer) | Sale | 4,500 | 182.10 | 819,450 |
| 2018-05-31 | Gilliland Dwight Gary (Director) | Sale | 1,263 | 181.28 | 228,961 |
| 2018-05-31 | Berberian Lance (SVP, Chief Information Officer) | Sale | 5,500 | 182.34 | 1,002,842 |
| 2018-05-30 | Gary M. Huff (CEO, LabCorp Diagnostics) | Sale | 1,610 | 182.50 | 293,823 |
| 2018-05-30 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Sale | 10,000 | 181.28 | 1,812,810 |
| 2018-05-23 | King David P (President & CEO) | Sale | 49,966 | 175.70 | 8,779,076 |
| 2018-05-23 | King David P (President & CEO) | Option Ex | 49,966 | 84.86 | 4,240,114 |
| 2018-04-23 | King David P (President & CEO) | Sale | 49,967 | 166.16 | 8,302,316 |
| 2018-04-23 | King David P (President & CEO) | Option Ex | 49,967 | 84.86 | 4,240,199 |
| 2018-04-04 | Gary M. Huff (CEO, LabCorp Diagnostics) | Option Ex | 3,500 | .00 | 0 |
| 2018-03-23 | King David P (President & CEO) | Sale | 49,967 | 164.97 | 8,243,255 |
| 2018-03-23 | King David P (President & CEO) | Option Ex | 49,967 | 84.86 | 4,240,199 |
| 2018-03-12 | Uthgenannt Lisa J (Chief Human Resources Officer) | Option Ex | 537 | .00 | 0 |
| 2018-03-12 | Dodson Edward T (Principal Accounting Officer) | Option Ex | 400 | .00 | 0 |
| 2018-03-12 | King David P (President & CEO) | Option Ex | 6,077 | .00 | 0 |
| 2018-03-12 | Eberts F Samuel Iii (Chief Legal Officer, Secretary) | Option Ex | 464 | .00 | 0 |
| 2018-03-12 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 1,627 | .00 | 0 |
| 2018-03-12 | Berberian Lance (SVP, Chief Information Officer) | Option Ex | 400 | .00 | 0 |
| 2018-02-12 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Sale | 8,400 | 167.85 | 1,409,940 |
| 2018-02-09 | Uthgenannt Lisa J (Chief Human Resources Officer) | Option Ex | 603 | .00 | 0 |
| 2018-02-09 | Dodson Edward T (Principal Accounting Officer) | Option Ex | 450 | .00 | 0 |
| 2018-02-09 | Ratliff John D (CEO, Covance Drug Development) | Option Ex | 6,100 | .00 | 0 |
| 2018-02-09 | King David P (President & CEO) | Option Ex | 7,543 | .00 | 0 |
| 2018-02-09 | Eberts F Samuel Iii (Chief Legal Officer, Secretary) | Option Ex | 520 | .00 | 0 |
| 2018-02-09 | Anderson Kerrii B (Director) | Sale | 3,300 | 166.10 | 548,123 |
| 2018-02-09 | Anderson Kerrii B (Director) | Option Ex | 3,300 | 75.63 | 249,578 |
| 2018-02-09 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 4,877 | .00 | 0 |
| 2018-02-09 | Berberian Lance (SVP, Chief Information Officer) | Option Ex | 3,497 | .00 | 0 |
| 2018-02-08 | Schechter Adam H (Director) | Sale | 1,263 | 169.29 | 213,813 |
| 2018-02-07 | Gary M. Huff (CEO, LabCorp Diagnostics) | Option Ex | 1,076 | .00 | 0 |
| 2018-02-07 | Uthgenannt Lisa J (Chief Human Resources Officer) | Option Ex | 326 | .00 | 0 |
| 2018-02-07 | Dodson Edward T (Principal Accounting Officer) | Option Ex | 246 | .00 | 0 |
| 2018-02-07 | Gilliland Dwight Gary (Director) | Option Ex | 1,263 | .00 | 0 |
| 2018-02-07 | Ratliff John D (CEO, Covance Drug Development) | Option Ex | 1,863 | .00 | 0 |
| 2018-02-07 | Parham Richelle P (Director) | Option Ex | 1,263 | .00 | 0 |
| 2018-02-07 | Kong Garheng (Director) | Option Ex | 1,263 | .00 | 0 |
| 2018-02-07 | Schechter Adam H (Director) | Option Ex | 1,263 | .00 | 0 |
| 2018-02-07 | Williams R Sanders (Director) | Option Ex | 1,263 | .00 | 0 |
| 2018-02-07 | King David P (President & CEO) | Option Ex | 4,220 | .00 | 0 |
| 2018-02-07 | Neupert Peter M (Director) | Option Ex | 1,263 | .00 | 0 |
| 2018-02-07 | Eberts F Samuel Iii (Chief Legal Officer, Secretary) | Option Ex | 296 | .00 | 0 |
| 2018-02-07 | Anderson Kerrii B (Director) | Option Ex | 1,263 | .00 | 0 |
| 2018-02-07 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 993 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
of LH listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Labcorp Holdings Inc. (symbol LH,
CIK number 920148) see
the Securities and Exchange Commission (SEC) website.